Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 566 participants.
Also called NCT01306214
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 566 participants
- Registry
-
NCT01306214 -
2010-019968-37
-
- Other papers using this trial's data
- Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Belgium, Bulgaria, Colombia, Czechia, Finland, France, Germany, Guatemala, Mexico, Peru, Russia, Spain, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT01306214. Randomized; double masking; primary purpose treatment. Start 2011-02 (registry gives no type); primary completion 2013-04 (actual). Results posted on 2014-06-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Obesity
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- BI 10773
- Intervention (Drug)
- BI 10773
- Lead sponsor
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01306214- Content hash
e5c91d60985075579957f0920baff5bcd0b238e46b30186c3b71936e0e427d39